Alembic Pharmaceuticals secures U.S. FDA approval for their Methotrexate Injection, confirming it is equivalent to a drug previously produced by Hospira. This marks the company's 236th U.S. FDA-approved Abbreviated New Drug Application (ANDA).

Alembic Pharma has secured USFDA approval for Dapagliflozin tablets, a diabetes drug similar to AstraZeneca's Farxiga. This move grants them a 180-day shared exclusivity in the market, targeting potential sales of up to $10.5 billion by December 2025.